Clinical trials: Community Pneumonia
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A Global Active Surveillance for Community Acquired Pneumonia
This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.
- Trial name
- NCT00929721
- Testing
- Blood draw, Chest X-ray, urine specimen
- Where
- Poland
- Volunteers
- 5,172 people
- Sponsor
- Pfizer
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Community Acquired Pneumonia, Staphylococcal Skin Infections
First Time in Man Trial for Friulimicin B
The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine.
- Trial name
- NCT00492271
- Testing
- Friulimicin B
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Infections, Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Complicated Community-acquired Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01669980
- Testing
- Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic…
- Trial name
- NCT02269644
- Testing
- Dalbavancin, Linezolid, Azithromycin
- Where
- United States
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
COVID-19, Undefined
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired…
- Trial name
- NCT04659122
- Testing
- AT-100
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Airway Therapeutics, Inc.
Pneumonia
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia
The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP).
- Trial name
- NCT00638859
- Testing
- Telithromycin (HMR3647)
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Sanofi
Community Acquired Bacterial Pneumonia
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- DEFINE-CABP (NCT02679573)
- Testing
- Delafloxacin, Moxifloxacin, Linezolid
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.
Serotype distribution and estimation of antimicrobial resistance in S. pneumoniae isolates and anticipated PCV7 and PCV13 coverage is difficult in Greece, because invasive isolates collected each year are limited and depict a…
- Trial name
- B1851065 (NCT01564771)
- Testing
- Non Intervention
- Where
- 21 sites in Greece
- Volunteers
- 293 people
- Sponsor
- Pfizer
Community-Acquired Pneumonia
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response.
- Trial name
- NCT00140023
- Testing
- Azithromycin microspheres 2.0 single dose
- Where
- 5 sites in Philippines
- Volunteers
- 47 people
- Sponsor
- Pfizer
Pneumonia
Community-Acquired Pneumonia (CAP) Surveillance
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
- Trial name
- NCT01416506
- Testing
- No Drug
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Bayer
Community Acquired Pneumonia, Bacterial Pneumonia
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization.
- Conditions
- Community Acquired Pneumonia, Bacterial Pneumonia, Cross Infection
- Trial name
- NCT00079885
- Testing
- tigecycline
- Volunteers
- 430 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer
Community-Acquired Infections
Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects
To purpose of this study is to assess the safety and tolerability of intravenous (IV) tigecycline in hospitalized subjects of Japanese descent with community-acquired pneumonia (CAP).
- Trial name
- NCT00575094
- Testing
- tigecycline
- Where
- 9 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer